+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-02-09Number of Pages: 114

Autologous Matrix-induced Chondrogenesis Market (Material - Hyaluronic Acid, Collagen, Polyethylene Glycol (PEG), and Poly Lactic-Co-Glycolic Acid (PGLA)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Global Autologous Matrix-Induced Chondrogenesis Market: Snapshot

Autologous matrix-induced chondrogenesis (AMIC) applies bi-layer collagen membrane through microfracture surgery to fix the damage to the articular cartilage damage. The AMIC procedure is a one-step that uses the microfracturing method, which is an established first-line treatment. The growing demand for minimal invasive procedures and a high prevalence of bone and joint disorders are expected to drive the growth of this market across the globe. According to the research report, the global autologous matrix-induced chondrogenesis market was valued at US$89.71 mn in 2015 and is expected to be worth US$186.38 mn by 2024. Between the years of 2016 and 2024, the global market is expected to progress at a CAGR of 8.6%.

autologous matrix induced chondrogenesis market

Collagen to Lead the Pack as its Usage Gains Value in Tissue Engineering Sector

On the basis of material the global autologous matrix-induced chondrogenesis market segmented into hyaluronic acid, collagen, polyethylene glycol (PEG), poly lactic-co-glycolic acid (PGLA) and others. Of these, the collagen segment held the largest share of this market in 2015, which was closely followed by hyaluronic acid. Collagen accounts for approximately 30% of all protein within the human body. Therefore, it is widely used for tissue engineering applications. High tensile strength and excellent handling properties of collagen are expected to drive the segment’s growth in the coming years.

Several players operating in the global market are focusing on developing technologically advanced products, which will ensure swift uptake of autologous matrix-induced chondrogenesis. For instance, In North America-based Geistlich Pharma, Inc. launched its line of bone harvesting instruments in February 2016. The line include products such as Geistlich SmartScraper, Geistlich SafeScraper TWIST, and Geistlich Micross.

North America to Dominate Global Market with Massive Pool of Geriatrics

In terms of geography, the autologous matrix-induced chondrogenesis market is fragmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the largest share of the autologous matrix-induced chondrogenesis market in 2015, followed by Europe. Increasing prevalence of various bone and joint disorders such as arthritis and rheumatoid arthritis amongst the geriatric population is likely to support the growth of autologous matrix-induced chondrogenesis market in North America.

Autologous matrix-induced chondrogenesis market in Europe, Germany, and France accounted more than 45% share of the total Europe autologous matrix-induced chondrogenesis market in 2015. Asia Pacific is also expected to be the fastest-growing market, expanding at a phenomenal CAGR compared to other regions. Increasing demand for minimal invasive procedures and increasing disposable income, along with increasing prevalence of cancer is expected to boost the autologous matrix-induced chondrogenesis market in the region during the forecast period.

The leading players operating in the global AMIC market are JRI Orthopaedics Ltd., BioTissue AG, Anika Therapeutics, Inc., B. Braun Melsungen AG, Arthro-Kinetics, Geistlich Pharma AG, CartiHeal, Matricel GmbH, Smith & Nephew plc and Zimmer Biomet Holdings. The competitive landscape of the global market is fairly consolidated as just a few players hold a significant share in the overall market. In the coming years, these players are expected to focus on expanding their reach by penetrating into developing countries of Brazil, India, South America, and Mexico. The report indicates that this move comes as the companies are trying to bring down the cost of their products by using the cheaper skilled labor in these nations and benefit from their booming medical tourism industry.

Section - 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Research Highlights

Section - 2 Assumptions and Research Methodology 
2.1 Assumptions and Acronyms Used
2.2 Research Methodology

Section-3 Executive Summary
3.1 Global AMIC Market: Market Snapshot
3.2 Global AMIC Market : Opportunity Map

Section-4 Market Overview
4.1 Global AMIC Market : Key Industry Developments

Section-5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
      5.1.2 Drivers
              5.1.2.1 Increasing Demand for Minimally Invasive Procedures
              5.1.2.2 Economically Efficient
              5.1.2.3 Rising Prevalence of Bone and Joint Disorders
              5.1.2.4 Aging Population
              5.1.2.5 Surge in Sports Injuries
              5.1.2.6 Reduces Life Risk and Faster Recovery
      5.1.3 Restraints
              5.1.3.1 Lack of Efficient Reimbursement System 
              5.1.3.2 Lack of Extensive Clinical Data
      5.1.4 Opportunity Analysis
              5.1.4.1 Emerging Economies to Offer Sustained Growth Opportunities
              5.1.4.2 Extending Distribution Network by Partnership/Acquisitions
5.2 Global AMIC Market Revenue Projection
5.3 Porter’s Five Forces Analysis
5.4 Value Chain Analysis
5.5 AMIC Market Outlook

Section-6 AMIC Market Analysis By Material
6.1 Key Findings
6.2 Introduction
6.3 Global AMIC Market Value Share Analysis, By Product Type
6.4 Global AMIC Market Forecast By Product Type
      6.4.1 Hyaluronic Acid
      6.4.2 Collagen
      6.4.3 Polyethylene glycol (PEG)
      6.4.4 Poly lactic-co-glycolic acid (PGLA)
      6.4.5 Others
6.5 Global AMIC Market Attractiveness Analysis By Material

Section-7 Global AMIC Market Analysis By Region
7.1 Global Regulatory Scenario
7.2 Global AMIC Market Value Share Analysis, By Region
7.3 Global AMIC Market Forecast, By Region
7.4 Global AMIC Market Attractiveness Analysis, By Region Type

Section-8 North America AMIC Market Analysis
8.1 Key Findings
8.2 North America AMIC Market Overview
8.3 North America Market Value Share Analysis, By Material
      8.3.1 North America Market Forecast By Material
8.4 North America Market Forecast By Country
8.5 North America Market Attractiveness Analysis
8.6 North America Market Trends

Section-9 Europe AMIC Market Analysis
9.1 Key Findings
9.2 Europe ABC Market Overview
9.3 Europe Market Value Share Analysis, By Material
      9.3.1 Europe Market Forecast By Material
9.4 Europe Market Forecast By Country
9.5 Europe Market Attractiveness Analysis
9.6 Europe Market Trends

Section-10 Asia Pacific AMIC Market Analysis
10.1 Key Findings
10.2 Asia Pacific AMIC Market Overview
10.3 Asia Pacific Market Value Share Analysis, By Material
      10.3.1 Asia Pacific Market Forecast By Material
10.4 Asia Pacific Market Forecast By Country
10.5 Asia Pacific Market Attractiveness Analysis
10.6 Asia Pacific Market Trends

Section-11 Latin America AMIC Market Analysis
11.1 Key Findings
11.2 Latin America AMIC Market Overview
11.3 Latin America Market Value Share Analysis, By Material
      11.3.1 Latin America Market Forecast By Material
11.4 Latin America Market Forecast By Country
11.5 Latin America Market Attractiveness Analysis
11.6 Latin America Market Trends

Section-12 Middle East and Africa AMIC Market Analysis
12.1 Key Findings
12.2 Middle East and Africa AMIC Market Overview
12.3 Middle East and Africa Market Value Share Analysis, By Material
      12.3.1 Middle East and Africa Market Forecast By Material
12.4 Middle East and Africa Market Forecast By Country
12.5 Middle East and Africa Market Attractiveness Analysis

Section-13 Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
      13.2.1. Anika Therapeutics, Inc. 
              13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.1.2. Financial Overview
              13.2.1.3. Product Portfolio
              13.2.1.4. SWOT Analysis
              13.2.1.5. Strategic Overview
      13.2.2 Arthro-Kinetics
              13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.2.2. Financial Overview
              13.2.2.3. Product Portfolio
              13.2.2.4. SWOT Analysis
              13.2.2.5. Strategic Overview
              13.2.3 B. Braun Melsungen AG 
              13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.3.2. Financial Overview
              13.2.3.3. Product Portfolio
              13.2.3.4. SWOT Analysis
              13.2.3.5. Strategic Overview
      13.2.4 BioTissue AG 
              13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.4.2. Financial Overview
              13.2.4.3. Product Portfolio
              13.2.4.4. SWOT Analysis
              13.2.4.5. Strategic Overview
      13.2.5 CartiHeal
              13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.5.2. Financial Overview
              13.2.5.3. Product Portfolio
              13.2.5.4. SWOT Analysis
              13.2.5.5. Strategic Overview
      13.2.6 Geistlich Pharma AG 
              13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.6.2. Financial Overview
              13.2.6.3. Product Portfolio
              13.2.6.4. SWOT Analysis
              13.2.6.5. Strategic Overview
      13.2.7 JRI Orthopaedics Ltd. 
              13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.7.2. Financial Overview
              13.2.7.3. Product Portfolio
              13.2.7.4. SWOT Analysis
              13.2.7.5. Strategic Overview
      13.2.8 Matricel GmbH
              13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.8.2. Financial Overview
              13.2.8.3. Product Portfolio
              13.2.8.4. SWOT Analysis
              13.2.8.5. Strategic Overview
      13.2.9 Smith & Nephew plc 
              13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.9.2. Financial Overview
              13.2.9.3. Product Portfolio
              13.2.9.4. SWOT Analysis
              13.2.9.5. Strategic Overview
      13.2.10 Zimmer Biomet Holdings
              13.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
              13.2.10.2. Financial Overview
              13.2.10.3. Product Portfolio
              13.2.10.4. SWOT Analysis
              13.2.10.5. Strategic Overview

List of Figures

Figure 01: Global Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, 2014–2024
Figure 02: Global AMIC Market Value Share Analysis, by Material, 2016 and 2024
Figure 03: Global Hyaluronic Acid Market Revenue (US$ Mn), 2014–2024
Figure 04: Global Collagen Market Revenue (US$ Mn), 2014–2024
Figure 05: Global PEG Market Revenue (US$ Mn), 2014–2024
Figure 06: Global PGLA Market Revenue (US$ Mn), 2014–2024
Figure 07: Global Others Market Revenue (US$ Mn), 2014–2024
Figure 08: AMIC Market Attractiveness Analysis, by Material
Figure 09: Global AMIC Market Value Share Analysis, by Region, 2016 and 2024
Figure 10: AMIC Market Attractiveness Analysis, by Region
Figure 11: North America Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, 2014–2024
Figure 12: North America Autologous Matrix-Induced Chondrogenesis Market Size Y-o-Y Growth Projections, 2015–2024
Figure 13: North America Market Attractiveness Analysis, by Country
Figure 14: North America AMIC Market Value Share Analysis, by Material, 2015 and 2024
Figure 15: North America AMIC Market Value Share Analysis, by Country, 2016 and 2024
Figure 16: North America Market Attractiveness Analysis, by Material
Figure 17: Europe Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, 2014–2024
Figure 18: Europe Autologous Matrix-Induced Chondrogenesis Market Size Y-o-Y Growth Projections, 2015–2024
Figure 19: Europe Market Attractiveness Analysis, by Country
Figure 20: Europe AMIC Market Value Share Analysis, by Material, 2015 and 2024
Figure 21: Europe AMIC Market Value Share Analysis, by Country, 2015 and 2024
Figure 22: Europe AMIC Market Attractiveness Analysis, by Material
Figure 23: Asia Pacific AMIC Market Size (US$ Mn) and Forecast, 2014–2024
Figure 24: Asia Pacific AMIC Market Size Y-o-Y Growth Projections, 2015–2024
Figure 25: Asia Pacific Market Attractiveness Analysis, by Country
Figure 26: Asia Pacific AMIC Market Value Share Analysis, by Material, 2015 and 2024
Figure 27: Asia Pacific AMIC Market Value Share Analysis, by Country, 2015 and 2024
Figure 28: Asia Pacific AMIC Market Attractiveness Analysis, by Material
Figure 29: Latin America AMIC Market Size (US$ Mn) Forecast, 2014–2024
Figure 30: Latin America AMIC Market Size Y-o-Y Growth Projection, 2014–2024
Figure 31: Latin America Market Attractiveness Analysis, by Country/Region
Figure 32: Latin America AMIC Market Value Share Analysis, by Material, 2015 and 2024
Figure 33: Latin America AMIC Market Value Share Analysis, by Country, 2015 and 2024
Figure 34: Latin America AMIC Market Attractiveness Analysis, by Material
Figure 35: Middle East & Africa AMIC Market Size (US$ Mn) Forecast, 2014–2024
Figure 36: Middle East & Africa AMIC Market Size Y-o-Y Growth Projections, 2015–2024
Figure 37: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 38: Middle East & Africa AMIC Market Value Share Analysis, by Material, 2015 and 2024
Figure 39: Middle East & Africa AMIC Market Value Share Analysis, by Country, 2016 and 2024
Figure 40: Middle East & Africa Market Attractiveness Analysis, by Material
Figure 41: Global Autologous Matrix-Induced Chondrogenesis Market Share Analysis By Company, (2015)

List of Tables

Table 01: Global Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, by Material, 2014–2024
Table 02: Global Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 03: North America Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, by Material, 2014–2024
Table 04: North America Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 05: Europe Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, by Material, 2014–2024
Table 06: Europe  Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 07: Asia Pacific Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, by Material, 2014–2024
Table 08: Asia Pacific Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 09: Latin America Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, by Material, 2014–2024
Table 10: Latin America Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 11: Middle East & Africa Autologous Matrix-Induced Chondrogenesis Market Size (US$ Mn) Forecast, by Material, 2014–2024
Table 12: Middle East & Africa Market Size (US$ Mn) Forecast, by Country, 2014–2024

Global Autologous Matrix-Induced Chondrogenesis Market: Scope and Methodology

This report on the global autologous matrix-induced chondrogenesis market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in this global market.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market size estimations involved in-depth study of services and product features of different types of services. Additionally, market related factors such as increasing demand for minimal invasive procedures and increasing prevalence of bone and joint disorder in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Autologous Matrix-Induced Chondrogenesis Market: Segmentation

Based on the material the market has segmented into hyaluronic acid, collagen, polyethylene glycol (PEG), Poly lactic-co-glycolic acid (PGLA) and others segment. Geographically, the global market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Japan, India, Saudi Arabia, UAE, Brazil, and Mexico.

Autologous Matrix-Induced Chondrogenesis Market: Geographical and Competitive Dynamics

The report also profiles major players in this market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Anika Therapeutics, Inc., Arthro-Kinetics, B. Braun Melsungen AG, BioTissue AG, CartiHeal, Geistlich Pharma AG, JRI Orthopaedics Ltd., Matricel GmbH, Smith & Nephew plc and Zimmer Biomet Holdings.

The global autologous matrix-induced chondrogenesis market has been segmented as follows:

Global Autologous Matrix-Induced Chondrogenesis Market, by Material

  • Hyaluronic Acid
  • Collagen
  • Polyethylene Glycol (PEG)
  • Poly lactic-co-glycolic acid (PGLA
  • Others

Global Autologous Matrix-Induced Chondrogenesis Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top